Experimental osteoarthritis HMGB1 blockade Hyaluronan Therapy Cartilage protection s u m m a r y Objective: The alarmin HMGB1 is an endogenous molecule that is released into the extracellular space upon trauma or cell activation. Extracellular HMGB1 initiates innate immune responses and besides mediating inflammation, has osteoclast-activating features and mediates pain, all important features in OA. The aim of this study was to examine the involvement of HMGB1 in experimental OA and to explore the effect of local anti-HMGB1-therapy on disease progression. Method: OA was induced in mice by surgical destabilization of knee joints and HMGB1 expression and localization was assessed by immunohistochemistry. For therapy evaluation, HMGB1-neutralizing antibodies were injected intraarticularly, alone or encapsulated in an injectable hyaluronan-based delivery vehicle. Human primary chondrocytes were stimulated with rHMGB1 and analyzed by qPCR and cytometric bead-array. Results: HMGB1 immunostaining of mouse OA joints demonstrated intra-and pericellular expression in chondrocytes, overlapping with proteoglycan depleted areas. Intra-articular injection of anti-HMGB1 antibodies had cartilage-protective effects, comparable to treatment with a TNF inhibitor. Direct and vehicle-based delivery had similar ameliorating effects and the effect of a single, early injection could not be enhanced by repeated injections. In vitro stimulation of chondrocytes with rHMGB1 affected chondrocyte function by inducing protein expression of IL6 and IL8 and downregulating mRNA of COL2A1. Conclusions: Our results suggest that the alarmin HMGB1 might be a new target for OA therapy development as we could observe an aberrant HMGB1 expression in mouse OA joints, stimulation of chondrocytes with rHMGB1 induced cytokine production and decreased matrix production and finally that HMGB1 blockade suppressed disease progression.
Introduction
Alarmins are a group of proteins known as endogenous mediators in innate immunity that play a pivotal role for the inflammatory state of cells and tissues. The prototypic alarmin highmobility group box 1 (HMGB1) is an evolutionary conserved protein that is highly expressed in the nuclei of all mammalian cells. HMGB1 can be passively released into the extracellular space during cell death or actively secreted during immune responses mainly by myeloid cells. Partly depending on its redox status, HMGB1 interacts with different receptors including toll like receptor (TLR) 2, TLR4, receptor for advanced glycated end products (RAGE) and CXCR4 1 . Best described in the literature is the interaction of disulfide HMGB1 (dsHMGB1) with TLR4 and the interaction of fully reduced, all-thiol (atHMGB1) with CXCR4 and RAGE, inducing cytokine production and cell migration, respectively 2e4 . HMGB1 may also form complexes with other molecules such as IL-1b, LPS or fibronectin fragments to modulate or enhance inflammation and increase the production of MMPs 5, 6 . Rheumatoid arthritis (RA) and osteoarthritis (OA) are two forms of chronic joint diseases resulting in destruction of cartilage tissue and hence in pain and loss of joint function. RA is highly inflammatory with an autoimmune component while OA entails low-grade inflammation and no autoimmunity has yet been described. It is likely that OA, defined by the clinical symptoms of cartilage degradation, is the result of different etiologies with both genetic, biological and mechanical components acting in synergy. In contrast to RA, the development of pharmacological therapies for OA has been slow and there is still a great need for new therapeutic options for people suffering from this common disease. Upregulation and extracellular expression of HMGB1 has been reported in both RA 7e9 and OA 10e12 and involvement of HMGB1 in pannus tissue formation, in destruction of cartilage and bone and direct effects on chondrocytes has been suggested 13e15 . With the increasing number of reports demonstrating pathogenic features of HMGB1 in multiple disease conditions, consequently HMGB1 has been suggested as a new therapeutic option. We previously demonstrated that HMGB1 neutralization with both polyclonal and monoclonal antibodies as well as with a peptide inhibitor, Box A, has beneficial effects on inflammation, pain and joint destruction in experimental models of arthritis 16, 17 . Surprisingly, there are no reports this far assessing the impact of HMGB1 blockade on OA progression. We thus set out to first explore and describe the involvement of HMGB1 in the pathogenesis of OA induced in mice by surgical destabilization of the joint and secondly to explore the effect anti-HMGB1-therapy on experimental OA progression.
Methods

Animals
Eight-week-old female C57Bl/6J mice, median weight 20g, (range 17e22g), were purchased from Charles River and housed 5 mice in each case in specific pathogenefree facilities at Karolinska University Hospital. Animals were acclimatized at least 7 days prior to any intervention. All experiments were approved by the Stockholm North Ethical Committee (Dnrs N535/11, N215/14). The mice had free access to water and standard rodent chow. A 12-h light/ dark cycle was maintained at all times. The mice were checked daily and the weights were monitored weekly throughout the experiment to ensure well-being.
Hyaluronan gel release system and anti-HMGB1 antibodies
The hyaluronan (HA) gel release system consists of two components; aldehyde-modified HA (HAA) and carbazate-modified polyvinyl alcohol (PVAC), which were prepared and used according to previously described methods 18, 19 . Briefly, HAA was dissolved at a concentration of 15 mg/ml in phosphate-buffered saline (PBS) and PVAC was dissolved at a concentration of 2.5 mg/ml in deionized water. The gel components were loaded into 1 ml sterile luer-lock syringes at a volume ratio of 3:2 for stoichiometric crosslinking of the active groups. The syringes were connected via an adapter and the components were mixed at room temperature for 15s to allow gelation to start prior to injection into the knee joints. The monoclonal mouse IgG2b anti-HMGB1 antibody 2G7 was produced inhouse according to previously described methods 17, 20 .
Experimental OA and treatments
OA was induced by surgically destabilizing the left knee joint through anterior cruciate ligament transection (ACLT) as described previously 18 . The surgery was performed under isoflurane anesthesia and postoperative pain relief was provided by administering buprenorphine (0.3 mg/ml) subcutaneously the first 24h after surgery. The mice could move around freely in the cages after surgery and were monitored daily. For histological and immunohistochemical analysis of OA progression in untreated mice, animals were sacrificed at 2 weeks, 6 and 10 weeks; (n ¼ 5 per group) and compared to non-operated, healthy mice. For therapy evaluation, the animals were sacrificed 8 weeks after surgery, and joints processed for histopathological examination. Animals were randomized into treatment groups before surgery by giving each mice a number and then draw numbers, where the first drawn number was assigned to group 1, the second to group 2, the third to group 3, the fourth to group 1, and so on. The operator was blinded to treatment regime. Treatments evaluated were: 1) one single intra-articular injection of anti-HMGB1 antibody (10 mg/ml) at the time of surgery (t ¼ 0) (n ¼ 16); 2) two injections of anti-HMGB1 at t ¼ 0 and t ¼ 2 weeks after surgery (n ¼ 7); 3) two injections of anti-HMGB1 in established disease (at t ¼ 2 weeks and t ¼ 4 weeks) (n ¼ 7); and 4) one single injection of anti-HMGB1 encapsulated in the injectable HA gel release system at t ¼ 0 (n ¼ 9). All injections were compared to injections of PBS (n ¼ 21), anti-TNF (etanercept 10 mg/ml) (n ¼ 6) or gel only (n ¼ 7) and data shown as median ± interquartile range. The experimental set up of therapy experiments are summarized in Fig. 3 . In addition, data were normalized to each experiment and pooled for a combined analysis. The normalization was carried out by subtracting the experiment average score from each individual's score and then dividing the residual by the experiment standard deviation. The statistical results presented are based on the normalized samples, but graphs are presented from individual experiments with un-normalized scores.
Histological assessment
Knee joints were fixed in 4% phosphate buffered formaldehyde for 24 h, decalcified in EDTA solution before dehydration and then embedded in paraffin. 6 mm thick frontal sections were cut and serial sections collected. For histological scoring 5 sections from the center of the joint were stained with Safranin-O/Fast green and semi-quantitatively scored according to recommendations for mice from the OARSI histopathology initiative 21 . All four quadrants of the joint were assessed separately and given a score ranging from 0 to 6 and the sum was calculated to achieve the total score of the joint. The sections were evaluated by two independent observers blinded to the identity of the specimens.
Immunohistochemistry
To detect expression of HMGB1 during OA progression in untreated mice, sections obtained at 2, 6 and 10 weeks post-surgery were stained with a rabbit polyclonal anti-HMGB1 antibody at 0.15 mg/ml (Abcam, Cambridge, UK). The HMGB1 expression was compared with healthy, non operated joints. Control for specificity was performed using an irrelevant IgG antibody in equal concentration (fractioned rabbit Ig no. XO936; DakoCytomation, Glostrup, Denmark). Sections were blocked with 2 % normal goat serum for 5 min to inhibit unspecific staining and in 3% H 2 O 2 for 15 min to reduce endogenous peroxide before incubation overnight with primary antibody. Positive staining was visualized with Bright Vision Ultimate plus kit using DAB as chromogen.
To evaluate expression of MHC-II, immunostaining with a biotin-conjugated anti-I-A antibody at 5 mg/ml (Pharmingen, BD Biosciences) was performed. Endogenous biotin was blocked with avidin for 30 min and with biotin for an additional 15 min (avidin/ biotin blocking kit; Vector Laboratories, Burlingame, CA, USA).
Positive staining was visualized with ABC Vectastain Elite kit. The overall HMGB1 expression in the joints was evaluated by semiquantitative scoring, where HMGB1 expression in the articular cartilage was graded 0e2 in each quadrant of the joint (medial tibia, medial femur, lateral tibia and lateral femur) as well as in medial and lateral menisci, synovia and ligaments. The maximum score sums up to 20. The sections were analyzed by one observer blinded to the identity of the specimens using a Leica microsystems microscope (Leica Microsystems, Wetzlar; Germany).
Slow release of anti-HMGB1 antibody from HA gels
The release kinetics of anti-HMGB1 antibody from HA gels in vitro was determined by encapsulating 2G7 (concentration 7.68 mg/ml) in HA gels (n ¼ 3) and detecting diffusion of the antibody. Gels with encapsulated 2G7 were placed in 1 ml PBS. All PBS (1 ml) was collected and changed to fresh PBS (1 ml) at time points 0h, 3h, 12h, 24h, 72h and 1 week. After collecting the 1 week sample, hyaluronidase was added to degrade the gel in order to release all remaining antibody. The IgG content in collected media was analysed by Bradford protein assay and cumulative IgG release was calculated for each time point.
Chondrocytes e isolation, culture conditions and stimulations
Chondrocytes were isolated from an OA patient undergoing knee replacement surgery at Karolinska University Hospital. All procedures were approved by the Institutional Ethical Committee (Solna, Stockholm, Sweden) and in compliance with the Declaration of Helsinki. Briefly, cartilage tissue was macroscopically dissected from the joint, carefully avoiding bone and soft tissue and cut into small pieces. After overnight enzymatic digestion of the extracellular matrix using a mix of collagenase I (Gibco, Invitrogen, Sweden), collagenase Invitrogen, Sweden (II) (Gibco, Invitrogen, Sweden) and hyaluronidase (SigmaeAldrich, Sweden), the suspension was filtered (80 mm) to remove debris and undigested tissue. The cells were washed in PBS before seeded in tissue culture plates for expansion. Chondrocytes were routinely cultured in DMEM-F12 (SigmaeAldrich) supplemented with 10% fetal calf serum, L-glutamin and penicillin streptomycin at 37 C and 5% CO 2 . Cells were used in stimulation experiments in passages 1e3 and trypsinized at 80% confluency. Expanded cells were cultivated in 3D culture systems modified from Johnstone et al. 22 . 200,000 cells were seeded in 10 ml complete DMEM-F12 in 24 well plates and left 4 h in 37 C, 5% CO 2 to adhere. Then 1 ml complete DMEM-F12 was added carefully and the cells left overnight to obtain a micromass culture. Chondrocyte cultures were challenged with dsHMGB1 (10 mg/ml HMGBiotech, Milan, Italy), LPS (10 ng/ml Sigma Aldrich, Sweden) or DMEM-F12 for 24h before cell culture supernatant was collected and mRNA extracted from cells.
Cytometric bead assay (CBA)
Cytokines in serum samples from OA mice and in human OA chondrocyte culture supernatants were analyzed using the human inflammation kit or CBA flexbeads for mouse (BD Biosciences, San Diego, CA, USA). In cell supernatatants TNF, IL-1b, IL6, IL8, IL12p70 and IL10 were analyzed and for mouse sera detection of TNF, IL-1a, IL-1b, IL6, KC, IFN-g and MCP-1 was performed. The kits were used according to the manufacturer's instructions. The samples were recorded using a CYAN flow cytometer and analyzed with FCAP Array software (BD version 3.1).
RTqPCR
Total RNA was isolated from stimulated chondrocytes using RiboZol (Amresco, OH, USA) according to manufacturer's instructions. mRNA was reverse transcribed using iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Molecular Probes, CA, USA) and real-time quantitative PCR was performed using the IQ TM SYBR® Green supermix (Bio-Rad, Hercules, CA, USA). Each PCR reaction included 500 nM forward and reverse primer each and 1 ng cDNA in 10 ml. The expression of cartilage matrix molecules collagen type II (COL2A1) and aggrecan (ACAN) and the cartilage degradation enzyme matrix metalloprotease-13 (MMP13) target genes were normalized to GAPDH expression and the resulting Ct values were analysed using the 2 ÀDDCt method. Samples were measured in technical PCR duplicates from triplicate stimulations. In vitro stimulation experiments were repeated 4 times using triplicate pellets for each stimulation. Primers used were: ACAN: 5 0 -TGGA-GAGGACTGTGTGGTGA-3' (Fwd), 5 0 -GTACCGCACCAGGGAATTGA-3 0 (Rev); MMP-13: 5 0 -TGCAGAGCGCTACCTGAGAT-3 0 (Fwd). 5 0 -AGACTGCATTTCTCGGAGCC-3' (Rev); COL2A1: 5 0 -TGGGTGTTCTATTTATTTATTGTCTTCCT-3' (Fwd), 5 0 -GCGTTGGACT-CACACCAGTTAGT-3' (Rev); GAPDH: 5 0 -CGCTCTCTGCTCCTCCTGTT-3 0 (Fwd), 5 0 -CCATGGTGTCTGAGCGATGT-3 0 (Rev).
Statistical analysis
Normality of data was tested using D'Agostino & Pearson omnibus normality test. All data sets except two injections of anti-HMGB1, anti-HMGB1 in established disease and anti-TNF treatments were normally distributed. To determine statistical significance in normally distributed data ANOVA and Dunett's post test was applied (PBS vs anti-HMGB1 and anti-HMGB1 in gel). The rest of the data sets included non-normal data, where non-parametric, two-tailed ANOVA was used for multiple comparisons using GraphPad Prism version 5 for Windows (GraphPad Software, San Diego, CA, USA). A P-value below 0.05 was considered statistically significant.
Results
HMGB1 expression and localization in relation to OA progression
To determine the presence and localization of HMGB1 during OA progression, immunohistochemical analysis of Safranin-O, HMGB1 and MHC-II expression in joint specimens from mice subjected to ACLT at different stages of OA progression (2, 6 and 10 weeks) was performed. OA progression as determined by OARSI histology score showed cartilage damage in all stages of disease, visualized as lack of Safranin-O staining [ Fig. 1(A) and (B) ]. Semi-quantitative scoring of HMGB1 expression in joints showed increased extranuclear HMGB1 expression at all stages of OA as compared to healthy controls [ Fig. 1(C) ]. HMGB1 expression was positively correlated to cartilage damage determined by the OARSI histology score, (rs ¼ 0.486, p ¼ 0.048) demonstrating intense HMGB1 expression in damaged OA joints [ Fig. 1(D) ]. Cytoplasmic and extracellular HMGB1 was localized in both articular cartilage and in other joint compartments, including synovia, ligaments and menisci during OA [ Fig. . 1(E)e(G)]. In articular cartilage, the expression of HMGB1 overlapped with areas of fibrillar, damaged cartilage and with areas with evident proteoglycan depletion. The HMGB1 expression colocalized with MHC-II expression, indicating that HMGB1 is upregulated when chondrocytes are in an activated or stressed state [ Fig. 2(A) and (B) ]. In the damaged cartilage areas, a distinct staining pattern of HMGB1 was observed, where HMGB1 was detected extracellularly without diffusion into the extracellular matrix. Instead, HMGB1 decorated the lacunae and pericellular matrix area [ Fig. 2(C) ]. Cytokine levels (TNF, IL-1a, IL-1b, IL6, KC, IFN-g and MCP-1) in serum samples from baseline and endpoint was analyzed by CBA, but levels were below detection limit (data not shown).
Cartilage-protective effects of local HMGB1-neutralizing therapy in experimental OA
To investigate the therapeutic potential of HMGB1 blockade in OA, we administered the monoclonal anti-HMGB1 antibody 2G7 intra-articularly to mice subjected to ACLT and evaluated the effect on OA progression. Three different treatment regimens were evaluated; a single injection at the time of surgery, two consecutive injections at the time of surgery and after 2 weeks and a late treatment regimen with one injection 2 weeks after surgery and an additional injection 4 weeks after surgery.
The effects of 2G7 treatment were compared to placebo injections of saline and to TNF blockade with soluble TNF-receptor (Enbrel ®) [ Fig. 3(A) ]. Intra-articular injections of the monoclonal anti-HMGB1 antibody showed cartilage protective effects compared to saline control (OARSI score 6.6 ± 2.1 vs 10.5 ± 1.6, p < 0.05), and equivalent effect as anti-TNF blockade (OARSI score 7.41 ± 4.3). The effect of a single, early injection could not be enhanced by repeated injections (OARSI score 6.71 ± 2.9). Late treatment in established disease did not diminish cartilage destruction compared to PBS (OARSI score 9.35 ± 5.5) [ Fig. 3(B) ]. 
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Encapsulation of anti-HMGB1 antibody in a slow release gel does not confer enhanced protection
To investigate the possibility of further boosting the effect of HMGB1 blockade, we encapsulated the anti-HMGB1 antibody in a modified hyaluronan gel. This gel formulation is injectable and results in slow release of the encapsulated drug. We have previously investigated the endogenous effects of this gel formulation in experimental OA and cartilage defects and demonstrated its antiinflammatory features 18 . We hypothesized that slow release of anti-HMGB1 in a slow release formulation could provide synergistic effects. Encapsulation of anti-HMGB1 antibody resulted in retention of antibody in the gel when observed in vitro over a 1week period. The antibody diffused from the HA gel at a constant rate and at the observation end-point the cumulative release was 1.9 mg of the loaded 2.1 mg. At the end point, the HA gel was degraded by hyaluronidases to release all anti-HMGB1 antibody and the remaining antibody pool was determined to 0.2 mg. This corresponds to a retention of 9,4% of the originally loaded antibody, which in vivo would be released as the gel degrades [ Fig. 4(A) ]. In vivo, intraarticular injection of anti-HMGB1 antibodies encapsulated in HA gel showed cartilage protective effects compared to PBS (OARSI score 7 ± 2.9 vs 10.5 ± 1.7, p < 0.05). However, there was no additive effect when compared to treatment with non-encapsulated anti-HMGB1 antibodies. Injection of the HA gel alone showed similar cartilage saving effects as anti-HMGB1 antibodies alone (OARSI score 4.7 ± 2.3) [ Fig. 4(B) and (C)].
In vitro stimulation with dsHMGB1 induces a proinflammatory phenotype in cultured osteoarthritic chondrocytes
To investigate whether HMGB1 exerts direct effects on chondrocytes, cells from an OA patient were cultured in 3D micromass cultures and challenged with dsHMGB1. For comparison, chondrocyte cultures were also stimulated with the known TLR4 ligand LPS. Cell supernatants were collected after 24 h and analysed for proinflammatory cytokines. Here, we could observe that stimulation with dsHMGB1 induced IL6 and IL8 expression in chondrocytes Cartilage saving effects of HMGB1 blockade in experimental OA. (a) Experimental design of treatment study. Intraarticular injections were performed once at t ¼ 0; twice at t ¼ 0 and 2 weeks; or in established disease at t ¼ 2 and 4 weeks. (b) HMGB-1 blockade and anti-TNF treatment displayed similar cartilage protective effects compared to PBS injection. Two injections at t ¼ 0 and after 2 weeks did not improve the cartilage score compared to one single injection at t ¼ 0. Anti-HMGB1 treatment in established disease with injection at t ¼ 2 weeks did not show cartilage protective effects. (c) Representative Saf-O stained sections from the different treatments. Graphs showing median ± interquartile range, *p < 0.05.
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[ Fig. 5(A) ], while TNF, IL1b, IL12p70 and IL10 were below detection limit (data not shown). Cell lysates were analyzed for mRNA levels of the matrix proteins collagen II (COL2A1) and aggrecan (ACAN) and the collagen II degrading enzyme MMP13. dsHMGB1 downregulated MMP13 and COL2A1 while ACAN was unaffected. On the contrary, for LPS the data pointed towards an increase of both anabolic and catabolic genes, although it did not reach statistical significance [ Fig. 5(B) ].
Fig. 4
Encapsulation of anti-HMGB1 antibody in a slow release gel does not confer enhanced protection. (a) Encapsulation of anti-HMGB1 antibody resulted in retention of antibody in the gel when observed in vitro. n ¼ 3. (b) Intraarticular injection of anti-HMGB1 antibodies encapsulated in HA gel showed cartilage protective effects. However, there was no additive effect when compared to treatment with non-encapsulated anti-HMGB1 antibodies or the gel alone.(c) Representative Saf-O stained sections from the different treatments. Graphs showing median ± interquartile range, *p < 0.05, **p < 0.005. HMGB1 stimulation of chondrocytes. Chondrocytes stimulated with dsHMGB1 induced IL6 (a) and IL8 (b) protein expression similar to LPS stimulation, while TNF, IL1b, IL12p70 and IL10 could not be detected (data not shown). (c) On mRNA level HMGB1 downregulated matrix degrading enzyme MMP13 and matrix protein collagen II (COL2A1) compared to unstimulated cells. On the contrary, LPS stimulation did not show statistically significant changes in gene expression, but indicated a potential upregulation of both degradation and production of extracellular matrix. Graphs showing mean with 95% CI, from n ¼ 4 separate experiments.
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Discussion
It has previously been demonstrated that the alarmin HMGB1 has proinflammatory and osteoclast-activating features 23 , that HMGB1 blockade ameliorates experimental inflammatory arthritis and that HMGB1 is aberrantly expressed in OA 11, 12, 24 . All contributing to the growing evidence of a role for HMGB1 in OA pathogenesis. The aim of this study was to corroborate the involvement of HMGB1 in OA disease progression and for the first time explore the effect of local anti-HMGB1-therapy in OA. We evaluated two delivery modalities; intra-articular injection of the monoclonal antibody alone, or the monoclonal antibody encapsulated in a slow release system. By immunohistochemical analysis we could reveal an aberrant expression of HMGB1 in osteoarthritic joints, and more importantly provide novel knowledge of the ameliorative effect of HMGB1 blockade on disease progression.
In accordance with reported findings of HMGB1 being expressed in human and bovine OA cartilage as well as synovial fluid from OA patients 10, 25, 26 , we recorded an altered HMGB1 expression in the joints of osteoarthritic mice, both early (2 weeks) after surgery as well as late (6 weeks). Similar results have been described for experimental inflammatory arthritis 9, 27 .
In particular, HMGB1 was localized to areas of cartilage damage as it overlapped with signs of proteoglycan depletion and with MHC II expression in chondrocytes. A distinct staining pattern was observed, where HMGB1 appeared to be secreted from the cells without diffusing into the extracellular space, but rather decorated the lacunae and pericellular matrix area. This could suggest that stressed or activated chondrocytes secrete HMGB1 in damaged cartilage. HMGB1 is heparin-binding and may be retained in the lacunae of chondrocytes by interacting with the heparin sulphate chains of perlecan in the pericellular matrix, resulting in the staining pattern observed. Mechanical compression of the cartilage matrix has been suggested as a regulatory pathway for chondrocyte activity, allowing or restricting the interaction of regulatory molecules such as growth factors sequestered in the pericellular matrix. It is possible that the interaction of HMGB1 with chondrocytes is regulated in a similar manner 28e30 . The redox status of HMGB1 regulates its biological function. To further define the role of HMGB1 in OA pathogenesis, we stimulated primary OA chondrocytes with dsHMGB1, the isoform associated with induction of inflammatory mediators. dsHMGB1 induced IL6 and IL8 production, but not TNF or IL-1b and a concomittant downregulation of the matrix proteins ACAN and COL2A1, indicating that HMGB1 could indeed contribute to joint degeneration. OA chondrocytes express TLR4, but they may be less sensitive compared to PBMCs or monocytes. It is known that dsHMGB1in addition to TLR4 binding needs interaction with co-receptors CD14 and MD2 to give full proinflammatory response 3, 31 . The expression of CD14 is lower in chondrocytes from arthritis patients compared to healthy 32 and CD14 expression in chondrocytes decrease with increasing passages 33 . Both innate chondrocyte expression levels and in vitro expansion effects in surface markers may explain the lack of TNF and IL1 secretion observed in this study. LPS, which is also a TLR4 ligand, induced IL6 and IL8 but did not display decreased matrix turnover. On the contrary, LPS showed a trend of increased overall turnover, i.e. both production and breakdown of extracellular matrix. This could depend on induction of differential signaling pathways by the endogenous TLR4 ligand HMGB1 as compared to the prototypic pathogen-derived TLR4 ligand LPS. This might be due to additional receptors, such as RAGE, being activated by HMGB1. However, exact effects of HMGB1 and its different redox isoforms need to be further studied. As accumulated data, both previously reported and ours, suggest HMGB1 to be a candidate drug target, we explored how intra-articular injection of the monoclonal anti-HMGB1 antibody 2G7 affected OA progression. 2G7 binds all HMGB1 redox isoforms and has proven effective in ameliorating a multitude of inflammatory and inflammationassociated conditions. We have previously engineered 2G7 into a chimeric, humanized antibody making 2G7 suitable for future clinical trials 20 . Our data suggest that blockade of HMGB1 is beneficial if treatment is performed early, potentially by blocking inflammation mediated by IL6 and IL8 and by suppressing the downregulation of matrix proteins as shown by the in vitro data. The experimental procedure used in this study, transection of the anterior cruciate ligament, results in OA development and is used as a model for OA developing in humans after joint injury. It is interesting to speculate that an early treatment with HMGB1 blockade after joint injury could suppress OA development in humans.
We knew from previous studies that the HA gel have displayed beneficial effects on cartilage 18, 19 and hypothesized that dual effects from gel and anti-HMGB1 could provide synergistic effects. Our data showed that both treatments were cartilage protective in themselves but they did not add together to further increase protection. Antibodies are known to be stable molecules with long half-life, hence the slow release system was not needed. However, there are other possible therapeutic molecules targeting HMGB1 that could be encapsulated and benefit from the slow release. Two such examples are A-box (antagonist to HMGB1) and FSSE (tetramer displaying anti-HMGB1effects) 34 .
In contrast to the single, early injection, additional injections of 2G7, or treatment initiated at later time points did not affect OA progression. We speculate that in conjunction to the joint trauma, early in the model, the HMGB1 being released is mainly dsHMGB1 functioning as a danger signal causing release of IL6 and IL8 in the joint, inflammation and a net catabolic state in the cartilage. Later during the disease progression, HMGB1 could still be detected in cartilage and blockade was no longer efficient. This is likely due to the inability of antibodies to reach the lacunae of chondrocytes. Recent studies have revealed that the all-thiol isoform of HMGB1 has regenerative capacity in bone, muscle and liver tissue 35, 36 but no such studies have been performed regarding cartilage tissue. Unfortunately, no antibodies available can distinguish between isoforms expressed in tissue and we were not able to detect which isoforms were present in OA joints at the different disease stages.
To conclude, we present the novel findings that HMGB1 expression is increased in experimental OA induced by ACLT, that dsHMGB1 has a immune modulating effect on chondrocytes affecting inflammatory cytokines and that in vivo blockade of HMGB1 showed cartilage protecting effect, both as a single injection and encapsulated in a slow release system based on an HA gel. However, the effect of a single, early injection could not be enhanced by repeated injections and blockade in established OA did not show any effect. This is to our knowledge the first report on anti-HMGB1 treatment for OA. Taken together with the previously reported anti-analgesic effects of HMGB1 blockade 37 , our data suggests that HMGB1 blockade is a highly interesting treatment option that deserves further studies. In particular for joint trauma patients at risk of developing subsequent OA.
